Kiniksa Pharmaceuticals International Plc (KNSA) Return on Equity ROE from the first quarter 2026 to first quarter 2025 and annually, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Kiniksa Pharmaceuticals International Plc  (NASDAQ: KNSA)

Kiniksa Pharmaceuticals International Plc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Kiniksa Pharmaceuticals International Plc in the first quarter 2026?
Kiniksa Pharmaceuticals International Plc achieved a return on average equity (ROE) of 13.26 % in its first quarter 2026, this is above KNSA's average return on equity of -20.63%.
Kiniksa Pharmaceuticals International Plc shareholder's equity over the 12 months ending in its first quarter 2026 are valued at $551 million

ROE has advanced compared to 11.48% in the fourth quarter 2025, due to net income growth.

Within the Major Pharmaceutical Preparations industry 46 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 1067, from total ROE ranking in the fourth quarter 2025 at 1095.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Equity Change 32.39 % 29.46 % 22.51 % 13.77 % -
Y / Y Net Income Change 164.57 % - - - -
Net Income (TTM) in Millions 73 59 36 5 -17
Return On Equity (TTM) 13.26 % 11.48 % 7.46 % 1.05 % -3.83 %
KNSA's Total Ranking # 1067 # 1095 # 1312 # 317 # 2065
Equity (TTM) in Millions 606 568 535 495 457
Seq. Equity Change 6.71 % 6.02 % 8.16 % 8.2 % 4.35 %
Seq. Net Income Change 59.11 % -22.98 % 3.38 % 108.83 % -

Back to KNSA Management Effectiveness >> KNSA's 5 Years Annual ROE >> Compare KNSA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 47
Sector # 121
Overall # 1067

Return On Equity Statistics
High Average Low
66.68 %
-20.63 %
-92.83 %
(Dec 31 2022)   (Sep 30 2019)





KNSA Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 568 438 439 396 185
Y / Y Equity Change 29.46 % -0.09 % 10.78 % 114.09 % -40.68 %
Net Income in Millions 59 -43 14 183 -158
Y / Y Net Income Change - - -92.32 % - -
Return On Equity 10.4 % -9.85 % 3.21 % 46.29 % -85.35 %

Back to KNSA Management Effectiveness >> KNSA's 5 Years Annual ROE >> Compare KNSA ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 10.4 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
KNSA's' Return on Equity at Yahoo Finance
KNSA's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for KNSA's Competitors
Subscribers only: Roe for Kiniksa Pharmaceuticals International Plc's Suppliers
Subscribers only: Return On Equity for KNSA's Customers




Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector ROE
Acadia Pharmaceuticals Inc   35.65 %
Spero Therapeutics Inc   35.58 %
Illumina Inc   33.99 %
Dexcom Inc   33.83 %
Rafael Holdings Inc  31.93 %
Solventum Corporation  30.71 %
Phibro Animal Health Corporation  30.60 %
Pro dex Inc   30.01 %
Incyte Corporation  29.20 %
Protalix Biotherapeutics inc   28.10 %
Collegium Pharmaceutical Inc   26.74 %
Pacs Group Inc   26.46 %
Johnson and Johnson  26.26 %
Engene Therapeutics Inc   25.83 %
Encompass Health Corporation  25.56 %
Chemed Corporation  25.33 %
Resmed Inc   24.76 %
Iradimed Corporation  24.48 %
Lantheus Holdings Inc   24.33 %
Prestige Consumer Healthcare Inc   24.20 %
Vertex Pharmaceuticals Inc  23.93 %
Catalyst Pharmaceuticals Inc   23.65 %
Xoma Royalty Corporation  23.64 %
Soleno Therapeutics Inc  22.85 %
Electromed Inc   22.41 %
Iqvia Holdings Inc   22.15 %
Msa Safety Inc  22.03 %
Neurocrine Biosciences Inc   21.64 %
Insulet Corporation  21.38 %
Universal Health Services Inc   21.22 %

Date modified: 2026-09-26T07:37:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.